TLDR
- TVTX shares rise as FILSPARI delivers durable proteinuria reductions in FSGS.
- Phase 3 extension data show sustained FILSPARI benefits over five years.
- More FSGS patients achieved complete and partial remission with FILSPARI.
- Patients switching from irbesartan showed rapid proteinuria improvements.
- Long-term DUPLEX findings strengthen FILSPARI’s FSGS treatment profile.
Travere Therapeutics (TVTX) stock traded at $47.04, gaining 4.06% after the company released new Phase 3 data. The results came from the ongoing DUPLEX open-label extension study of FILSPARI in focal segmental glomerulosclerosis. The findings showed sustained proteinuria reductions and growing remission rates during long-term follow-up.
Travere Therapeutics, Inc., TVTX
FILSPARI Maintains Long-Term Proteinuria Reduction
Travere presented the latest findings at the European Renal Association 2026 Congress in Glasgow. The data covered patients who continued FILSPARI treatment after the double-blind phase. The extension study tracked outcomes for up to three additional years.
Patients who started FILSPARI during the double-blind period maintained proteinuria reductions throughout the extension phase. As treatment continued, more patients achieved clinically meaningful proteinuria targets. The results highlighted durable responses across approximately five years of total follow-up.
The company reported that 37.5% of continuing FILSPARI patients achieved complete remission at some point during the study. Additionally, 87.5% reached partial remission during the combined study period. The long-term safety profile remained consistent with previous observations.
Patients Switching to FILSPARI Show Rapid Response
Patients who initially received irbesartan moved to FILSPARI after completing the double-blind period. Following the transition, they experienced rapid reductions in proteinuria. These improvements remained sustained throughout the extension study.
Among patients who switched treatments, 28.9% achieved complete remission during either study phase. Meanwhile, 74.6% achieved partial remission across the combined treatment period. The response pattern closely matched outcomes seen in earlier FILSPARI users.
The earlier double-blind phase also demonstrated stronger remission outcomes for FILSPARI. Complete remission occurred in 18.5% of FILSPARI-treated patients. In comparison, only 7.5% of irbesartan-treated patients achieved the same result.
DUPLEX Study Adds Long-Term Evidence for FILSPARI
The Phase 3 DUPLEX study remains the largest interventional trial conducted in FSGS. The trial enrolled 371 patients aged eight to 75 years. Researchers compared FILSPARI with maximum labeled-dose irbesartan over a treatment period of up to 108 weeks.
Participants entered the study after a washout period and then received randomized treatment assignments. Researchers evaluated efficacy and safety outcomes throughout the study duration. The primary endpoint measured the rate of change in estimated glomerular filtration rate through Week 108.
FSGS is a rare kidney disease marked by progressive scarring and protein leakage into urine. The condition can lead to declining kidney function and eventual kidney failure. Sustained proteinuria reduction remains an important treatment objective for affected patients.
Beyond the FSGS data, Travere also plans to present preclinical findings involving a gddY mouse model. The research identified a mechanism showing how FILSPARI may block gdIgA deposition in the kidney. These additional findings expand the company’s ongoing kidney disease research efforts.
The latest extension results strengthen the growing evidence supporting FILSPARI in FSGS treatment. The study demonstrated sustained proteinuria reductions, increasing remission rates, and a consistent safety profile. The findings add further long-term clinical data for Travere Therapeutics and its lead kidney disease therapy.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
